Becker's Healthcare August 27, 2024
GLP-1s reduced mortality and complications from cardiovascular events, according to a study published Aug. 22 in Diabetes, Obesity and Metabolism: A Journal of Pharmacology and Therapeutics.
Researchers from Taiwan analyzed data from more than 3 million patients with obesity in the TriNetX Global Network between Jan. 1, 2016 and March 31, 2024. Of those patients, 12,123 individuals who received GLP-1 medication were matched with the same number of individuals who had not received it.
Patients who received the medication had a significantly lower risk of mortality, ischemic heart disease, heart failure, arrhythmias,...
Today's Sponsors
Today's Sponsor